Altimmune, Inc.
June 26, 2025 - by Joey Ramson
$ALT shares are plummeting today after mixed Phase 2b trial results for pemvidutide. Although successful in achieving its primary endpoint by resolving MASH for up to 59.1% of patients, when it came to the other key endpoint of improving fibrosis while not worsening MASH, pemvidutide was unable to demonstrate a statistically significant difference.
